Bladder cancer

Current Opinion in Oncology

Volumn 15, Issue 3, 2003, Pages 227-233

  Borden Jr , Lester S ^a   Clark, Peter E ^a   Hall, M Craig ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TUMOR MARKER; VINBLASTINE;

BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; META ANALYSIS; METASTASIS; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HUMANS; INCIDENCE; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 0038686981     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200305000-00009     Document Type: Review

References (65)

1. Pashos CL, Botteman MF, Laskin BL, et al.: Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002, 10:311-322.
2. Jemal A, Thomas A, Murray T, et al.: Cancer statistics 2002. CA Cancer J Clin 2002, 52:23-47.
3. American Cancer Society: Cancer facts and figures, 2001. Available at: http://www.cancer.org/downloads/STT/F&F2001.pdf. Accessed December 20, 2002.
4. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49:33-64.
5. Schairer C, Hartge P, Hoover RN, et al.: Racial differences in bladder cancer risk: a case control study. Am J Epidemiol 1988, 128:1027-1037.
6. Mungan NA, Kiemeney LA, van Dijck JA, et al.: Gender differences in stage distribution of bladder cancer. Urology 2000, 55:368-371.
7. Mungan NA, Aben KK, Schoenberg MP, et al.: Gender differences in stage-adjusted bladder cancer survival. Urology 2000, 55:876-880.
8. Hartge P, Silverman D, Hoover R, et al.: Changing cigarette habits and bladder cancer risk: a case control study. J Natl Cancer Inst 1987, 78:1119-1125.
9. Zeegers MPA, Tan FES, Dorant E, et al.: The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000, 89:630-639.
10. Aveyard P, Adab P, Cheng KK, et al.: Does smoking status influence the prognosis of bladder cancer? a systematic review. Br J Urol 2002, 90:228-239.
11. Ozen H, Hall MC: Bladder cancer. Curr Opin Urol 2000, 12:255-259.
12. Saad A, Hanbury DC, McNicholas TA, et al.: A study comparing various non-invasive methods of detecting bladder cancer in urine. BJU 2002, 89:369-373.
13. Boman H, Hedelin H, Holmang S: Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002, 167:80-83.
14. Lokeshwar VB, Soloway MS: Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001, 165:1067-1077.
15. Kausch I, Bohle A: Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2002, 2002, 41:15-29. An excellent review of the current knowledge of potential prognostic markers in bladder cancer.
16. Williams SG, Buscarini M, Stein JP: Molecular markers for diagnosis, staging, and prognosis of bladder cancer. Oncology 2001, 15:1461-1476. An excellent review of the carcinogenesis and progression of urothelial carcinoma on a molecular level and the molecular markers that are potentially useful for diagnosis and prognosis of bladder cancer.
17. Bassi P: BCG (bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg Oncol 2002, 11:77-83.
18. Bohle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003, 169:90-95.
19. Pawinski A, Sylvester R, Kurth KH, et al.: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996, 156:1934-1941.
20. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette. Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970. A meta-analysis of randomized clinical studies involving transurethral resection plus BCG versus transurethral resection alone or transurethral resection plus a treatment other than BCG for patients with nonmuscle-invasive bladder cancer. Results showed that BCG does appear to reduce the risk of progression to muscle-invasive disease.
21. Solsona E, Iborra I, Ricos JV, et al.: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999, 161:1120-1123.
22. Tolley DA, Parmar MK, Grigor KM, et al.: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 1996, 155:1233-1238.
23. Rajala P, Kaasinen E, Raitanen M, et al.: Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - Finnbladder III long-term results. J Urol 2002, 168:981-985. A trial demonstrating the long-term efficacy of a single dose of epirubicin immediately postoperatively after transurethral resection in reducing the risk of recurrence in superficial bladder cancer compared with transurethral resection alone or transurethral resection plus intefferon-α.
24. Mulders PF, Hoekstra WJ, Heybrook RP, et al.: Prognosis and treatment of T1G3 bladder tumors: a prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer 1994, 30A:914-917.
25. Heney NM, Ahmed S, Flanagan MJ, et al.: Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083-1086.
26. Borkowski A: Superficial bladder cancer T1G3: the choice of treatment. Br J Urol 2002, 89:623-627.
27. Frazier HA, Robertson JE, Paulson DF: Complications of radical cystectomy an urinary diversion: a retrospective review of 675 cases in 2 decades. J Urol 1992, 148:1401-1405.
28. Herr HW: Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol 1991, 145:40-44.
29. Allard P, Bernard P, Fradet Y, et al.: The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998, 81:692-698.
30. Smith G, Elton RA, Chisholm GD, et al.: Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. Br J Urol 1986, 58:659-663.
31. Dutta SC, Smith JA Jr, Shappell SB, et al.: Clinical understaging of high risk non-muscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001, 166:490-493.
32. Pagano F, Bassi P, Galetti TP, et al.: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathologic study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991, 145:45-50.
33. Schips L, Augustin H, Ziguener RE, et al.: Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002, 59:220-223.
34. Herr HW: The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999, 162:74-76.
35. Dalbagni G, Herr HW, Reuter VE: Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002, 60:822-825. A small, prospective study that demonstrated the improved accuracy in clinical staging of bladder cancer by performing a second, restaging transurethral resection.
36. Vieweg J, Gschwend JE, Herr HW, et al.: pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999, 161:449-454.
37. Hautmann RE, Paiss T: Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy. J Urol 1998, 159:1845-1850.
38. Hara I, Miyake H, Hara S, et al.: Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder. Jpn J Clin Oncol 2002, 32:14-18.
39. Sanchez-Ortiz RF, Huang WC, Mick R, et al.: An interval longer than 12 weeks between diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003, 69:110-115.
40. Gschwend JE, Dahm P, Fair W: Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 2002, 41:440-448. Long-term survival results of 686 patients who underwent radical cystectomy with a direct comparison of disease-specific survival and overall survival. Ten-year disease-specific survival was 72.9% for organ-confined disease, and prognostic factors for disease-specific survival are reported.
41. Yossepowitch O, Dalbagni G, Golojanin D, et al.: Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol 2003, 169:177-181.
42. Vallancien G, El Fettouh HA, Cathelineau X, et al.: Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002, 168:2413-2417.
43. Matin SF, Gill IS: Laparoscopic radical cystectomy with urinary diversion: completely intracorporeal technique. J Endourol 2002, 16:335-341.
44. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al.: Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989, 142:1448-1453.
45. Mameghan H, Fisher R, Mameghan J, et al.: Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995, 31:247-254.
46. Shelley MD, Barber J, Wilt T, et al.: Surgery versus radiotherapy for muscle invasive bladder cancer [abstract] (Cochrane Review). In The Cochrane Library, CD002079, 2002. Oxford: Update Software.
47. Rodel C, Grabenbauer GG, Kuhn R, et al.: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002, 20:3061-3071. Long-term results of trimodality (transurethral resection, radiation, and chemotherapy with or without salvage cystectomy) therapy in 415 patients with bladder cancer, demonstrating its effectiveness as an alternative to cystectomy.
48. Shipley WU, Kaufman DS, Zehr E, et al.: Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002, 60:62-67. Long-term results of trimodality therapy in patients with muscle-invasive bladder cancer, demonstrating its effectiveness and bladder preservation rates.
49. Stein JP, Liekovsky G, Cote R, et al.: Radical treatment of invasive bladder cancer: long term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
50. Bradley BA, Wajsman A: The role of chemotherapy and radiation in organ-preservation strategies for muscle-invasive bladder cancer. World J Urol 2002, 20:167-174.
51. Sternberg CN: Neo-adjuvant and adjuvant chemotherapy of bladder cancer: is there a role? Ann Oncol 2002, 13(suppl 4):273-279.
52. Hall RR, MRC Advanced Bladder Cancer Group: Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M), and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract]. Am Soc Clin Oncol: 2002 Annual Meeting Summaries, p. 54. An important presentation reporting the updated results of a prospective, randomized trial of 976 patients with muscle-invasive bladder cancer, assessing the utility of neoadjuvant CMV. Results currently indicate a small but statistically significant survival benefit for patients in the neoadjuvant chemotherapy arm.
53. Millikan R, Dinney C, Swanson D, et al.: Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005-4013. A phase III trial of 140 patients with high-risk but respectable disease comparing the timing of adjuvant M-VAC chemotherapy. There was no difference in survival whether patients received two courses preoperatively and three courses postoperatively versus all five courses postoperatively.
54. Bassi P, Ferrante GD, Piazza N, et al.: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999, 161:1494-1497.
55. Calabro F, Sternberg CN: High risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 2002, 12:441-448.
56. Sternberg CN, de Mulder PHM, Schornagel JH, et al.: Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer. Protocol No. 30924. J Clin Oncol 2001, 19:2638-2646.
57. Von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
58. 2 every 21 days with an overall response rate of 58%.
59. Bellmunt J, Gullillem V, Paz-Ares L, et al.: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2000, 18:3247-3255.
60. Pecasides D, Glotos J, Bountouroglou N, et al.: Weekly chemotherapy with docetaxel, gemcitabine, and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002, 13:243-250. Phase II trial of a combination of docetaxel, gemcitabine, and cisplatin was associated with an impressive overall response rate of 65.6%, substantiating the need for further evaluation in phase III randomized trials.
61. Logothetis CJ, Hossan E, Recondo G, et al.: 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res 1994, 14:1265-269.
62. Siefker-Radtke AO, Millikan RE, Tu S, et al.: Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002, 20:1361-1367.
63. Sternberg CN, Calabro F, Pizzocaro G, et al.: Chemotherapy with an every-2-week regiment of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001, 92:2993-2998. A study of gemcitabine and paclitaxel administered every 2 weeks in patients who had failed to respond to M-VAC produced a median survival of 12 months and 8 months after failure in patients who had received M-VAC in adjuvant or neoadjuvant and metastatic settings, respectively, demonstrating its effectiveness as a second-line chemotherapy regimen.
64. Vaughn DJ, Manola J, Dreicer R, et al.: Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896). Cancer 2002, 95:1022-1027.
65. Ricci S, Galli L, Chioni A, et al.: Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 2002, 95:1444-1450.